On November 19, 2018 Bexion Pharmaceuticals, Inc., a clinical – stage biopharmaceutical company focused on rare brain and solid tumors, reported that a clinical oral report followed by poster review and a second case study poster were presented at the Society of Neuro – Oncology (SNO) Annual Meeting held November 16 – 18 in New Orleans, LA (Press release, Bexion, NOV 19, 2018, View Source [SID1234531577]). The SNO Annual Meeting brings together more than 2600 research ers and clinicians in the field of neuro – oncology.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Bexion’s representation:
High – Grade Glioma O utcomes in the Phase 1 BXQ – 350 Trial of Cancer – Selective SapC – DOPS Nanovesicles
Vinay Puduvalli, MD, Professor and Director, Division of Neuro – Oncology, The Ohio State University Comprehensive Cancer Center gave an oral presentation on November 16 th discussing the safety outcomes of High Grade Glioma (HHG) patients from a Phase 1a BXQ – 350 trial (NCT02859857). This was followed by a traditional poster viewing.
Initial Experience in Ependymoma with Investigational Cancer – Targeting BXQ – 350 SapC – DOPS Nanovesicles: A Rare Tumor Case Study
During a poster presentation on Saturday November 17 th , John Villano MD, Director, Clinical Neuro – Oncology Research Program, Markey Cancer Center and Professor of Medicine, University of Kentucky HealthCare discussed the safety profile in a rare tumor type resulting from a Phase 1a BXQ – 350 trial (NCT02859857).
"Bexion was honored to participate in the SNO Annual meeting. We are exc ited to have presented new BXQ – 350 data from our Phase 1 program by our Principal Investigators ," stated Dr. Ray Takigiku, Founder and CEO of Bexion.
About BXQ – 350
BXQ – 350 is a unique formulation of a synthetically produced, human lysosomal protein, Saposin C (sphingolipid activator protein, or SapC), and the phospholipid dioleoylphosphatidylserine (DOPS).